Advertisement: Cambridge Network mid banner
Advertisement: HCR Hewitsons mid banner
Advertisement: Excalibur Healthcare mid banner
Advertisement: SATAVIA mid banner
Advertisement mid banner S-Tech 1
Barr Ellison Solicitors – commercial property
Advertisement: Mogrify mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Kao Data Centre mid banner
Cambridgeand mid banner advertisement
ARM Innovation Hub
Advertisement: EBCam mid banner
Advertisement: partnersand mid banner
Advertisement: RSM mid banner
Advertisement: CJBS mid banner
Mid banner advertisement: BDO
Advertisement: Simpsons Creative
7 April, 2022 - 21:29 By Tony Quested

AstraZeneca to unveil blitz on cancer at New Orleans showcase

Cambridge life science world leader AstraZeneca is using ‘The Big Easy’ to show how it is getting tough on cancer and its causes.

The Big Biotech innovator has pledged to transform the oncology treatment landscape with a diverse early pipeline and novel combinations. Its next-wave medicines to advance oncology care will be unveiled from April 8-13 at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.

AstraZeneca says the initial data for novel molecules show promising anti-cancer activity and will be showcased at the meeting along with the company’s strategy to attack cancer from multiple angles.

It reveals that data from 60 presentations, including five oral and three mini-oral presentations will be detailed, spanning the company’s immuno-oncology, DNA Damage Response and Antibody Drug Conjugate scientific platforms. 

This includes key data shared from three potential new medicines that illustrate the company’s innovative approach to designing molecules that address key challenges in treating cancer – including the ability to target different, complementary mechanisms.

Susan Galbraith, executive VP, Oncology R & D at AstraZeneca, said: “We are serious about leading a revolution in oncology, which is why we continue to pioneer new ways to target cancer earlier and with greater precision for the benefit of patients. 

“Our data at AACR from next-wave Immuno-Oncology medicines, PARP inhibitors and antibody drug conjugates demonstrate the potential of our diverse portfolio and reflect our vision to target cancer from every angle.”

The company’s focus is on some of the most challenging cancers. It says: “It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry with the potential to catalyse changes in the practice of medicine and transform the patient experience.”

Newsletter Subscription

Stay informed of the latest news and features